NZ611614A - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms

Info

Publication number: NZ611614A
Authority: NZ; New Zealand
Prior art keywords: compositions; associated symptoms; methods; amyloid plaque; plaque associated
Prior art date: 2010-12-02

Application number

NZ611614A

Other languages

English (en)

Inventor

David Holtzman

Jungsu Kim

Hong Jiang

Adam Eltorai

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-02

Filing date

2011-12-02

Publication date

2015-07-31

2011-12-02 Application filed by Univ Washington filed Critical Univ Washington

2015-07-31 Publication of NZ611614A publication Critical patent/NZ611614A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Neurology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

NZ611614A 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms NZ611614A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41906010P	2010-12-02	2010-12-02
US201161548542P	2011-10-18	2011-10-18
PCT/US2011/063121 WO2012075422A2 (en)	2010-12-02	2011-12-02	Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number	Publication Date
NZ611614A true NZ611614A (en)	2015-07-31

Family

ID=46172597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ611614A NZ611614A (en)	2010-12-02	2011-12-02	Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country	Link
US (2)	US20140037638A1 (2)
EP (1)	EP2646053A4 (2)
JP (1)	JP2014502276A (2)
KR (1)	KR20140017513A (2)
CN (1)	CN103338786A (2)
AU (1)	AU2011336360A1 (2)
BR (1)	BR112013013723A2 (2)
CA (1)	CA2819679A1 (2)
MX (1)	MX2013006116A (2)
NZ (1)	NZ611614A (2)
RU (1)	RU2013130002A (2)
SG (1)	SG190952A1 (2)
WO (1)	WO2012075422A2 (2)
ZA (1)	ZA201303996B (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2847218A4 (en) *	2012-05-08	2015-12-30	Univ Ramot	APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2016054247A1 (en)	2014-09-30	2016-04-07	Washington University	Tau kinetic measurements
EP3452074A4 (en) *	2016-05-03	2019-12-11	University of South Florida	COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
CA3042236A1 (en)	2016-10-28	2018-05-03	Washington University	Anti-apoe antibodies
EP3655026A4 (en)	2017-07-17	2021-07-28	Janssen Biotech, Inc.	ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
AU2020282792B2 (en) *	2019-05-28	2025-12-04	Banner Health	ApoE antibodies, fusion proteins and uses thereof
US20240400659A1 (en) *	2021-10-19	2024-12-05	Bioatla, Inc.	Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) *	2022-11-30	2025-12-11	リージェンツオブザユニバーシティオブミネソタ	ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) *	2024-07-17	2026-01-22	Jn Biosciences Llc	Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3265577B2 (ja) *	1992-10-13	2002-03-11	デューク・ユニバーシティ	アポリポ蛋白ｅの４型イソ型の測定法
RU2006122946A (ru) *	2003-11-28	2008-01-10	Астразенека Аб (Se)	Антитела
EP1736162A1 (en) *	2004-03-30	2006-12-27	Renomedix Institute Inc.	Remedy for prion disease and method of producing the same
US20070248599A1 (en) *	2006-02-21	2007-10-25	Jordan Tang	Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) *	2006-12-14	2008-06-19	Forerunner Pharma Research Co., Ltd.	Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) *	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2542581A4 (en) *	2010-03-01	2014-01-22	David Gladstone Inst	APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF

2011
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2012075422A3 (en)	2012-10-04
MX2013006116A (es)	2013-10-17
EP2646053A2 (en)	2013-10-09
AU2011336360A1 (en)	2013-07-04
ZA201303996B (en)	2015-10-28
US20140037638A1 (en)	2014-02-06
KR20140017513A (ko)	2014-02-11
CA2819679A1 (en)	2012-06-07
WO2012075422A2 (en)	2012-06-07
JP2014502276A (ja)	2014-01-30
BR112013013723A2 (pt)	2019-09-24
EP2646053A4 (en)	2014-05-28
US20160355581A1 (en)	2016-12-08
RU2013130002A (ru)	2015-01-10
CN103338786A (zh)	2013-10-02
SG190952A1 (en)	2013-07-31

Legal Events

Date	Code	Title	Description
2015-11-27	PSEA	Patent sealed
2015-12-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2016 BY CPA GLOBAL Effective date: 20151222
2016-10-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2017 BY CPA GLOBAL Effective date: 20161021
2018-06-29	LAPS	Patent lapsed

Publication	Publication Date	Title
NZ611614A (en)	2015-07-31	Compositions and methods for treating amyloid plaque associated symptoms
CY1124307T1 (el)	2022-07-22	Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2011009539A (es)	2012-02-21	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MY163521A (en)	2017-09-15	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2012062925A3 (en)	2012-07-12	Compounds and methods for treating pain
NZ602219A (en)	2014-10-31	Methods and compositions for treating degos’ disease
WO2013061161A3 (en)	2013-11-07	New combination therapies for treating neurological disorders
EA201001771A1 (ru)	2011-06-30	Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX355543B (es)	2018-04-20	Macrociclos peptidomiméticos.
WO2012173846A3 (en)	2013-03-21	Peptidomimetic macrocycles
SG179095A1 (en)	2012-04-27	Novel assay for the detection of amyloid beta peptides
PH12013501490A1 (en)	2019-03-13	Methods for diagnosing and treating eye-length related disorders
MX356728B (es)	2018-06-12	Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
IN2015DN00370A (2)	2015-06-12
WO2012170945A3 (en)	2013-01-31	Methods for modulating kallikrein (klkb1) expression
IN2014DN08385A (2)	2015-05-08
MX2012014163A (es)	2013-05-17	Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
IN2015DN03969A (2)	2015-10-02
SG194235A1 (en)	2013-12-30	Methods of predicting the development of complement-mediated disease
MA32416B1 (fr)	2011-06-01	7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
PH12013502563A1 (en)	2014-01-27	Dha and epa in the reduction of oxidative stress
WO2009098355A8 (en)	2009-10-08	Novel use of probiotics
MX364626B (es)	2019-05-03	Péptidos miméticos.
EP3449917A3 (en)	2019-06-05	Tapentadol for preventing chronification of pain
PH12014501052A1 (en)	2014-06-30	Methods and compositions for the treatment of diabetes and related symptoms